Treats chronic idiopathic constipation (CIC). ANDA 218056, held by Zydus Lifesciences. Prucalopride Succinate.
As of Nov 16, 2026, ANDA 218056 (Prucalopride Succinate), held by Zydus Lifesciences, was first approved by FDA on Aug 7, 2025, with 1 approved supplement and 0 published complete response letters.
Prucalopride tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 7, 2025 | Original application | Approved | None posted |
| Prucalopride SuccinateEQ 1MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Prucalopride SuccinateEQ 2MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Jan 29, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 7, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters